The present study investigates global transcriptional changes in frontal cortex area 8 in incidental Lewy Body disease (iLBD), Parkinson disease (PD) and Dementia with Lewy bodies (DLB). We identified different coexpressed gene sets associated with disease stages, and gene ontology categories enriched in gene modules and differentially expressed genes including modules or gene clusters correlated to iLBD comprising upregulated dynein genes and taste receptors, and downregulated innate inflammation. Focusing on DLB, we found modules with genes significantly enriched in functions related to RNA and DNA production, mitochondria and energy metabolism, purine metabolism, chaperone and protein folding system and synapses and neurotransmission (particularly the GABAergic system). The expression of more than fifty selected genes was assessed with real time quantitative polymerase chain reaction. Our findings provide, for the first time, evidence of molecular cortical alterations in iLBD and involvement of several key metabolic pathways and gene hubs in DLB which may underlie cognitive impairment and dementia.
INTRODUCTION
Lewy body diseases (LBDs), which include Parkinson's disease (PD) and dementia with Lewy Bodies (DLB), are neurodegenerative disorders, characterized by the presence of intracytoplasmic neuronal inclusions named Lewy bodies (LB) and abnormal neurites containing a-synuclein species and aggregates (32, 41, 46, 49, 64) . Nonmotor symptoms such as sleep disorders, loss of olfaction and autonomic alterations may precede the appearance of motor symptoms; cognitive impairment and dementia can occur at advanced stages of PD, and dementia is compulsory in DLB. Braak stages of a-synuclein pathology distribution are useful to delineate a framework to interlink LBDs into a spectrum. Stages 1-3 can be associated with pre-motor symptoms although in most cases the presence of LBs and neurites in selected regions of the medulla oblongata, pons and midbrain is an incidental finding at autopsy. The term incidental PD or Lewy Body disease (LBD) (iPD or incidental LBD [iLBD]) refers to those early stages of LBD pathology with no apparent clinical symptoms, corresponding to the early stages of LBD spectrum (22) . PD is usually manifested at stages 4 and 5 once the involvement of the substantia nigra reaches determinate thresholds of neuronal loss and dopaminergic denervation of the striatum is manifested. Cognitive impairment can be detected at stages 5 and 6 in PD, whereas DLB cases are categorized as Braak stages 5 and 6 of LB pathology (11, 84) . However, no exact correlation exists between Braak stages and clinical symptoms linked to cognitive impairment and dementia (14, 23, 28, 47, 48, 65, 77) , this fact suggesting that factors other than LBs and neurites play a cardinal role in the pathogenesis of LBDs. Concomitant pathologies, particularly those linked to Alzheimer's disease (AD), have also been suggested to explain variations in the degree of cognitive impairment in DLB (8, 17, 47, 50, 70, 71) .
Decreased dopaminergic, noradrenergic serotoninergic and cholinergic innervation of the cerebral cortex are contributory factors to the appearance of cognitive impairment and dementia in PD. They are due to the loss of vulnerable neurons in the substantia nigra, locus coeruleus, raphe nuclei and nuclei of the basal forebrain including the basal nucleus of Meynert, respectively (13, 43, 45, 53, 54, 62, 89) . However, recent studies demonstrate the primary impairment of several metabolic pathways in the cerebral cortex in PD and other LBDs, such as synaptic transmission, mitochondria and energy metabolism, purine metabolism, protein synthesis, lipid composition of membranes and inflammation, among others (19, 20, 26, 28, 31, 34-36, 61, 63, 68, 74, 79, 94) .
Studies of transcriptomic profiling in LBDs have been mainly focused on the typically affected subcortical regions such as substantia nigra, locus coeruleus and striatum in PD (7, 18, 40) . Cortical regions have received much less attention with studies limiting their outcome to lists of differentially expressed genes (DEGs) (59) . Still, this approach has allowed the discovery of the brain expression of olfactory and taste receptors and their deregulation in the cerebral cortex and substantia nigra in PD (33, 42) .
Here, we set out to investigate global transcriptomic changes occurring in the frontal cortex of cases of iLBD, PD and DLB relative to middle-aged individuals with no neurological symptoms and with no alterations at the postmortem examination. We focused particularly on identifying gene coexpression modules showing correlation with the spectrum of LB disorders. By applying weighted gene coexpression network analysis (WGCNA) (57) to microarray data, we determined the transcriptome structure in the frontal cortex and identified coexpression modules correlated to iLBD, PD and DLB. Validation of hubs and selected altered pathways was carried out with real time quantitative polymerase chain reaction (RTqPCR).
MATERIAL AND METHODS BRAIN SAMPLES
Brain tissue was obtained from the Institute of Neuropathology Brain Bank (HUB-ICOIDIBELL Biobank) and the Hospital Clinic-IDIBAPS Biobank following the guidelines of Spanish legislation on this matter and of the local ethics committee. Processing of brain tissue has been detailed elsewhere (29, 80) . The postmortem interval between death and tissue processing was between 3 h and 15 h. One hemisphere was cut in 1-cm-thick coronal sections, and selected areas of the encephalon were rapidly dissected, frozen on metal plates over dry ice, placed in individual air-tight plastic bags, numbered with water-resistant ink and stored at 2808C until use for biochemical studies. The other hemisphere was fixed by immersion in 4% buffered formalin for 3 weeks for morphologic studies. Neuropathological diagnosis was categorized following current staging classifications for LBD (1, 10, 78) . For AD-related pathology, neurofibrillary tangles (NFTs) (9) and phases of AD-related bamyloid plaques (91) were assigned. Only cases with "typical" staging of LBD pathology were selected for study.
Two series of cases were used. The first one served for microarray studies. RNA samples from frontal cortex (area 8) of middle aged (MA) (n 5 8, 4 men, 4 women; age: 67.5 6 12.8 years), iLBD (n 5 4, 1 men, 3 women; age: 71.2 6 4.5 years), PD (n 5 8, 4 men, 4 women, age: 67.8 6 8.8 years) and DLB (n 5 8, 5 men, 3 women; age: 72.3 6 8.6) cases were analyzed using the Affymetrix microarray platform and the Genechip Human Gene 1.1 ST Array (Affymetrix, Santa Clara, CA, USA). The second series of cases was used for RT-qPCR validation of altered expression of selected genes. Cases used for gene validation were iLDB (n 5 5, 4 men, 1 woman; age: 66.8 6 8.9 years) at stages 3 and 4, and PD cases (n 5 9, 3 men, 6 women; age: 77.1 6 4.7 years) at stages 5 and 6, DLB cases (n 5 9, 8 men, 1 woman; age 76.44 6 5.77 years). PD cases had suffered from parkinsonism and had received treatment during the duration of the disease but did not have dementia. MA cases had not suffered from neurological disease and the neuropathological examination did not reveal abnormalities (n 5 15, 6 men, 9 women, age 64.4 6 15.5 years). In addition, four cases with rapid clinical course DLB (rapid course DLB [rpDLB]; two years of less of disease duration) (2 men and 2 women, age 73.7 6 2.2 years) were chosen for a few selective studies (37, 38) .
Cases with associated pathologies such as vascular diseases (excepting mild atherosclerosis and arteriolosclerosis), TDP-43 proteinopathy, infection of the nervous system, brain neoplasms, systemic and central immune diseases, metabolic syndrome and hypoxia were excluded from the present study. Regarding ADrelated pathology, rare NFTs and b-amyloid deposits were found in iLBD (Braak stages 0-II; Thal phases 0-I); Braak stages I-III and Thal phases 0-3 were observed in PD; Braak stages 0-V and Thal phases 0-5 occurred in DLB. MA cases had not suffered from neurologic, psychiatric or metabolic diseases (including metabolic syndrome), and did not have abnormalities in the neuropathological examination excepting NFT pathology stages I-II and phases 0-2 of b-amyloid plaques.
RNA EXTRACTION
Purification of RNA was carried out with RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) following the protocol provided by the manufacturer. During purification, samples were treated with RNase-free DNase Set (Qiagen) to avoid later amplification of genomic DNA. The concentration of each sample was obtained from A260 measurements with Nanodrop 1000. RNA integrity was tested using the Agilent 2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA, USA). Values of RNA quality (RNA integrity number [RIN] values) were from 7 to 8.8 in the first series and from 6.2 to 8.2 in the second series.
MICROARRAY ANALYSIS
Affymetrix microarray platform and the Genechip Human Gene 1.1 ST Array was used to analyze gene expression patterns on a whole-genome scale on a single array with probes covering several exons on the target genes. Starting material was 200 hg of total RNA from each sample. Sense ssDNA was generated from total RNA with the Ambion WT Expression Kit from Ambion (Carlsbad, CA, USA), according to the manufacturer's instructions. Sense ssDNA was fragmented, labeled and hybridized to the arrays with the GeneChip WT Terminal Labeling and Hybridization Kit from Affymetrix. Chips were processed on an Affymetrix GeneTitan platform.
Preprocessing of raw data and statistical analyses were performed using Bioconductor packages in R programming environment. We read CEL files from Affymetrix arrays, corrected the background and summarized and normalized the data with the robust microarray method implemented in the Bioconductor Limma package (81) . Then, fold change and SEs were assessed by fitting a linear model (using the lmFit function in Limma package) for each gene. Genes with empirical Bayes t test P-values at a level of 0.01 were selected. Multiple testing correction was performed by adjusting P-values for false discovery rate (FDR) using the Benjamini and Hochberg method (BH).
GENE ENRICHMENT SCORE
The average expression values of different transcripts of the same gene were used for gene enrichment scores and weighted gene coexpression network analysis. Only genes in the upper 25% percentile of standard deviation of expression among samples were assessed. For probes mapping to multiple genes we fused all gene ids into one and that was considered a "gene" in the network analysis but not for functional annotation, gene ontology (GO) enrichment and protein-protein interactions (PPI) analysis, for which all individual ids were used.
An enrichment score per gene (5), which is a measure of specificity of a gene for a particular group, disease state in our study, was calculated relative to the rest of the groups tested. Briefly, the method is based on computing linear model coefficients contrasting all groups pair-wise. These coefficients represent a measure of difference between two groups in which more distant categories present higher coefficient values usually associated with lower Pvalues. The enrichment score of a gene in a group is the sum of its significant coefficients against all other groups.
The enrichment score for each of the 5114 genes under study was calculated after obtaining the linear models for microarray data with the LIMMA package (81) considering a linear coefficient statistically significant at uncorrected P-value lower than 0.01.
WEIGHTED GENE COEXPRESSION NETWORK ANALYSIS
WGCNA was done in R using the WGCNA library (57) . We first constructed a gene coexpression network based on pair-wise correlation of gene expression using all samples at the same time or independently for each disease condition. Not all network topologies fitted with the scale-free topology model (i.e., the iLBD network). Therefore, all subsequent analysis based on the coexpression network constructed with all samples used a softpower threshold of 5. We identified modules of genes based on their topological overlap dissimilarity with their connection strengths in the weighted network (44, 66) . Using the dynamic tree-pruning algorithm, 23 initial modules were obtained; genes not assigned to any module were labeled in gray. After merging all modules with highly correlated eigengenes (Pearson correlation >/5 0.8), 13 final modules were obtained. Module eigengenes were correlated to LBD diagnostic. The P-values were obtained from a general multivariate lineal model including additional control variables (i.e., age, sex, RIN, PMI and batch).
Gene enrichment analysis
GO enrichment analysis was performed using GOstats (27) . Differentially expressed genes with uncorrected P-values <0.01 for each contrast were used for GO analysis. All genes belonging to a particular gene coexpression module were also used for independent GO analyses. P-values for categories were adjusted considering FDR using BH with the p.adjust function in R.
PROTEIN-PROTEIN INTERACTION NETWORK
Assumed protein-protein interaction was obtained with BioGrid, latest release. Subnetworks of genes were obtained using the function-induced subgraph from the R library rTRM (73) . Only nodes with evidence of physical interaction in humans were considered. Networks were analyzed and visualized using Cytoscape (87) .
REAL-TIME PCR
RT-qPCR assays were conducted in duplicate on 1000 hg of cDNA samples obtained from the retrotranscription reaction, diluted 1:20 in 384-well optical plates (Kisker Biotech, Steinfurt, GE) utilizing the ABI Prism 7900 HT Sequence Detection System (Applied Biosystems). Parallel amplification reactions were carried out using 20x TaqMan Gene Expression Assays and 2x TaqMan Universal PCR Master Mix (Applied Biosystems). TaqMan probes used in the study are shown in Supporting Information Table 1 . The reactions were performed using the following parameters: 508C for 2 minutes, 958C for 10 minutes, 40 cycles at 958C for 15 s and at 608C for 1 minute. TaqMan PCR data were captured using the Sequence Detection Software (SDS version 2.2, Applied Biosystems). Subsequently, threshold cycle (CT) data for each sample were analyzed with the double delta CT (DDCT) method. First, delta CT (DCT) values were calculated as the normalized CT values for each target gene in relation to the endogenous controls bglucuronidase (GUS-b) and X-prolyl aminopeptidase P1 (XPNPEP1). These housekeeping genes were selected because they show no modifications in several neurodegenerative diseases in human postmortem brain tissue (4, 25) . A similar pattern was observed using GUS-b and XPNPEP1 for normalization (data not shown). The mean of GUS-b and XPNPEP1 was used for correction and representation. Finally, DDCT values were obtained with the DCT of each sample minus the mean DCT of the population of control samples (calibrator samples). The fold-change was determined using the equation 2-DDCT (33).
STATISTICAL ANALYSIS FOR RT-QPCR
The normality of distribution of the mean fold-change values obtained with RT-qPCR for every region and stage between controls and PD cases was analyzed with the Kolmogorov-Smirnov test. The nonparametric Mann-Whitney test was performed to compare each group when the samples did not follow a normal distribution and the unpaired student's T-test was used for normal variables. Statistical analysis was performed with GraphPad Prism version 5.01 (La Jolla, CA, USA) and Statgraphics Statistical Analysis and Data Visualization Software version 5.1 (Warrenton, VA, USA). Differences between groups were considered statistically significant at P-values: *P < 0.05, **P < 0.01 and ***P < 0.001. Additionally, BH-FDR adjusted P-values were obtained using the p.adjust function in R.
RESULTS
Differential gene expression and gene enrichment score in frontal cortex area 8 in iLBD, PD and DLB We contrasted gene expression values of all possible pair-wise comparisons among all diagnostic groups. We selected differentially expressed genes or DEGs (see methods). We found most DEGs occurred between DLB and the rest of groups; in particular, most were genes downregulated in DLB compared to controls, followed by genes upregulated in DLB. Considering nominal P-values lower than 0.01, PD and iLBD showed fewer DEGs than DLB. Considering multiple-testing adjusted P-values < 0.05, only DLB cases produced differential expressed genes (DEG) genes comparable to controls, and no gene survived that threshold in iLBD and PD (Supporting Information Table 2 ).
We performed GO enrichment analysis focused on biological process categories for each group of DEGs independently in upregulated and downregulated genes (Supporting Information Table 3 ).
To summarize all pair-wise group comparison in one statistic, we calculated a gene enrichment score for each of the 5114 genes analyzed. The advantage of this approach is the possibility of highlighting genes that are differentially expressed in one group relative to all other groups. The score of a given gene summarizes differences in expression levels between comparisons among all four groups of samples. Positive or negative scores are associated with an increase or a reduction in expression, respectively, of each gene in a given group relative to the rest of the groups. We obtained 1914 genes with an enrichment score other than 0 in at least one of the groups. As revealed by clustering analysis, we found that DLB presented the highest number of genes with higher enrichment scores ( Figure 1A ). In agreement with the proportion of DEGs described above, gene scores in DLB were mostly negative ( Figure  1A ). The fifty top upregulated and top downregulated genes in DLB are listed in Supporting Information Table 4 .
The main upregulated genes in frontal cortex in iLBD were associated with axonemal dynein complex assembly and taste receptors, whereas the main downregulated genes were linked to inflammation ( Table 1) .
The main upregulated genes in frontal cortex in DLB compared with controls were categorized into cellular development and DNA/RNA metabolism genes. The main downregulated genes in frontal cortex in DLB compared with controls were grouped into synapsis and neurotransmission, chaperone and protein folding, mitochondria and energy metabolism, purine metabolism and inflammation (Table 2) .
Weighted gene coexpression network analysis
Weighted gene coexpression network was constructed using the expression values of 5114 genes with variable expression among the 28 samples. Thirteen uncorrelated (r < 0.8 gene modules were identified and labeled by colors and numbers (M1 to M13). The genes not assigned to any particular coexpression module were assigned to M0 or "gray" ( Figure 1B) .
We obtained the most representative pattern of gene expression across all samples for each one of these modules by calculating the eigengene (i.e., the first principal component). The eigengene of each module was then correlated with the LBD spectrum (iLBD, PD and DLB) obtaining an eigengene significance for each module ( Figure 2A ). Three modules, M4-lightcyan (157 genes), M6-tan (215 genes) and M10-darkred (23 genes) were negatively correlated with iLBD. M3-green (226 genes), M11-royalblue (23 genes) were positively and M10-darkred negatively, correlated to PD were negatively correlated with iLBD. M3-green (226 genes) and M11-royalblue (23 genes) were positively and M10-darkred negatively, correlated to PD. Three other modules, M3-green, M5-brown and M9-salmon, correlated significantly with DLB. M5-brown correlated negatively with DLB and contained 766 genes. M3-green and M9-salmon correlated positively with DLB and contained 226 and 51 genes, respectively ( Figure 2B ). None of our identified disease-correlated modules were also correlated with age, indicating that our disease associated modules are not significantly confounded by transcriptomic changes produced by normal ageing. Of note, one module, M7-midnightblue, was negatively correlated with age.
Module characterization
Four strategies were used: (1) Identification of top highly connected genes (or hubs) in each module, (2) Assessment of overlaps with available published brain modules to correlate present LBD-associated modules to brain-related biological categories, (3) Identification of enriched GO among genes in each module and (4) Subdivision of each module into subnetworks based on available knowledge concerning physical PPI networks of human proteins.
Top hub genes
MSN, UGT2B11, lysosomal protein transmembrane 5 (LAPTM5) gene was the top hub genes in the iLBD-associated modules M4-lightcyan, M10-darkred and M6-tan, respectively. MSN encodes for Moesin, a molecule that links cytoskeleton to membrane and which is a suggested phosphorylation target of LRRK2. UGT2B11 encodes a UDP-glucuronosyltransferase and LAPTM5 is a lysosomal gene recently identified as a hub node in the protein-interaction network obtained from DEGs in locus ceruleus in PD patients vs. healthy donors (18) . Hub genes in M3-green and M11-royalblue, PD-associated modules, are genes with unknown function. ATP6V1B2 and ATPase, H1 transporting, lysosomal 70 kDa, V1 subunit A (ATP6V1A) and stress-induced-phosphoprotein 1 (STIP1) were top hub genes for M5-brown and M9-salmon, respectively, linked to DLB modules. ATP6V1A encodes a component of vacuolar ATPase which mediates the acidification of intracellular organelles including endosomes, lysosomes, the trans- Golgi network and synaptic vesicles, thus enabling a plethora of functions such as zymogen activation, endocytosis, synaptic transmission and protein transport (12) . STIP1 (HOP) is implicated in assisting the function of chaperone protein interaction with HSP70 and HSP90 (72) (Supporting Information Table 5 ).
Overlap of modules with reported brain-related categories: specific cell populations and particular diseases
Module M6-tan and M4-lightcyan were highly enriched in markers of microglia (15) . M5-brown and M9-salmon DLB-associated modules were found enriched in neuronal and microglial markers (24, 58) (Figure 3 , Supporting Information Table 6 ). Other modules identified in our study, but not correlated with LBD, showed enrichment in particular cell types. For instance, M2-blue module was enriched in oligodendrocyte markers whereas M1-cyan and M7-midnightblue were enriched in neuronal and glial cell markers. These observations support the biological consistency of our network and the robustness of the method to build similar transcriptomic modules using different sources of data. M6-tan modules presented enrichment in genes that was also deregulated at early stages of AD (75) . Moreover, module M5-brown showed overlap with deregulated gene sets and modules reported in AD (6, 60) . These confluences suggest commonalities involving multiple processes in these neurodegenerative diseases. In fact, DLB is largely associated with AD-related pathology, and DLB cases in the present series had associated AD pathology.
Identification of enriched GO among genes in each module
We also attempted to relate genes in modules to particular GO. Consistent with the microglial nature of this module, genes in M6-tan were highly enriched in GO categories related to immune system and inflammation. Similarly, M4-lightcyan was also enriched in categories related to inflammatory defence response. Module M5-brown showed highly significant enrichment in GO categories related to synaptic transmission and energy metabolism, among others. Genes in M9-salmon module presented a highly significant enrichment in GO categories related to protein folding and heatshock chaperone activity. Interestingly, the age associated M7-midnightblue module was enriched in GO categories such as hormone response, oxidative stress and learning, among others. Supporting Information Table 7 shows the full list of categories in modules 3, 5, 6, 9 and 11. Only few genes composed M11-royalblueand M10-darkred for proper GO analysis, but those modules contained taste 2 receptor members (TAS2R10, TAS2R4, TAS2R50) and nine olfactory receptors, respectively.
Putative subnetworks of protein-protein interactions
We intersected genes from each coexpression module with PPI databases to identify putative subnetworks with biological relevance within modules. Genes in M6-tan, M4-lightcyan, M5-brown and M9-salmon each produced notable PPI subnetworks composed of 44, 51, 302 and 21 genes, respectively (representing 25.7%, Figure 4A ). M4-lightcyan included a subnetwork with CDK2, MSN and TP53 as top degree nodes ( Figure 4B ). Heat-shock related proteins encoded by genes STIP1, heat shock 70 kDa protein 5 (glucoseregulated protein, 78 kDa) (HSPA5), AHSA1 and heat shock 70 kDa protein 1A (HSPA1A) were the highest connected nodes in the M9-salmon PPI subnetwork ( Figure 4C ). M5-brown module contained a large PPI subnetwork with several nodes including proteins encoded by tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide (YWHAB), TP1A, glycogen synthase kinase 3 beta (GSK3B), proteasome (prosome, macropain) subunit, alpha type, 3 (PSMA3) and SNCA, among others ( Figure 4D ). These results allow for better characterization of selected LBDassociated modules. M5-brown globally downregulated in DLB and enriched in neuronal markers and in genes mostly related to synaptic transmission and energy metabolism presented ATP6V1B2 and YWHAB as top hub genes in the transcriptomic and PPI networks, respectively. Other highly connected molecules were GSK3B, PSMA3, ATP6V0D1, triosephosphate isomerase 1 (TPI1), ATP6V1A and SNCA. Finally, an M9-salmon module, globally upregulated in DLB, was characterized by significant enrichment in genes involved in heat-shock protein folding and microglial markers, and was nuclearized around the hub gene STIP1 in both transcriptomic and PPI networks. Other highly interacting proteins were encoded by DnaJ (Hsp40) homolog, subfamily A, member 1 (DNAJA1), DnaJ (Hsp40) homolog, subfamily B, member 1 (DNAJB1), DnaJ (Hsp40) homolog, subfamily B, member 4 (DNAJB4), HSPA5, HSAPA6, AHSA1 and HSPA1A.
RT-qPCR validation
LAPTM5, a top gene in M6, was found not to be deregulated in iLBD, PD and DLB. ATP6V1A, one of the top genes in M5, was downregulated in DLB (1.03 6 0.25 vs. 0.57 6 0.52, P 5 0.007). The expression of STIP1, one top gene in M9, was not significantly altered in DLB but only in a subset of rpDLB (see later) and in PD (1.03 6 0.28 vs. 1.75 0.70, P 5 0.006); however, mRNA expression of DNAJA1 and DNAJB1, other top genes in the same module, was significantly increased in DLB (see later). SYK, the principal PPI in M6 was not deregulated in iLBD, PD and DLB (MA: 1.06 6 0.51, iLBD: 0.81 6 0.58, PD: 1.02 6 0.38, DLB: 1.47 6 0.93).
TPI1, a PPI member of module 5, was upregulated in PD (1.02 6 0.20 vs. 1.29 6 0.14, P 5 0.004). No significant modifications in the expression mRNA levels were observed for selected PPI members of M5 and M9 modules in DLB. However, several members were deregulated in a subpopulation of DLB cases characterized by their rapid course and classified as rpDLB. Regarding M5, upregulated genes in rpDLB were GSK3B (1.03 6 0.22 vs. 1.62 6 0.88, P 50.046), whereas PSMA3 (1.01 6 0.15 vs. 0.57 6 0.05, P 50.000) and YWHAB (1.01 6 0.15 vs. 0.69 6 0.22, P 5 0.007) were downregulated. Genes representative of PPI in M9 were upregulated in rpDLB: HSPA1A (1.01 6 0.40 vs. 3.10 6 2.00, P 5 0.007), HSPA5 (1.06 6 0.38 vs. 2.14 6 0.83, P 5 0.003) and STIP1 (1.03 6 0.28 vs. 2.07 6 1.10, P 5 0.009). Abnormal regulation of the dynein cluster was assessed by RTqPCR in LBDs with particular attention on iLBD. TASRs were assessed in iLBD, PD and DLB. Three biological functions, RNA/ DNA metabolism, chaperone and protein folding, and synaptic neurotransmission, were selected for validation in DLB. We extracted those pathways and clusters from each of those categories that appeared in the corresponding module and disease in which the category appeared as significantly enriched.
Regarding dyneins, dynein axonemal assembly factor 1 (DNAAF1), dynein axonemal heavy chain 11 (DNAH11), dynein axonemal heavy chain 2 (DNAH2), dynein axonemal heavy chain 7 (DNAH7) and dynein axonemal intermediate chain 1 (DNAI1), but not dynein axonemal heavy chain 5 (DNAH5) and dynein axonemal heavy chain 9 (DNAH9), were significantly upregulated in iLBD when compared with MA. Interestingly, upregulation also occurred in PD and DLB. Taste receptor TAS2R5 and TAS2R13 were upregulated and downregulated, respectively, in iLBD; TAS2R10 upregulated in PD, and TAS2R4, TAS2R5, TAS2R14, TAS2R10 and TAS2R13 significantly upregulated in DLB (Table 3) .
Moving on to iLBD, expression of allograft inflammatory factor 1 (AIF1) (which encodes IBA-1) was downregulated, as predicted, in frontal cortex (control: 1.07 6 0.41, iLBD: 0.57 6 0.20, P 5 0.018). Focusing on DLB, polyribonucleotide nucleotidyltransferase 1 (PNPT1), poly(A) polymerase alpha (PAPOLA), RELA (proto-oncogene, NF-kB subunit) and DOT1 like histone lysine methyltransferase (DOT1L) mRNAs, all of them involved in RNA/ DNA metabolism, but not lysine acetyltransferase 2A (KAT2A), were significantly upregulated in DLB (Table 4) . Importantly, PNPT1 and RELA were upregulated in iLBD, and KAT2A was added in PD (Table 4) .
Chaperone members DNAJA1, DnaJ (Hsp40) homolog, subfamily A, member 4 (DNAJA4), DNAJB1, heat shock 70 kDa protein 4 (HSPA4), heat shock 70 kDa protein 6 (HSP70B) (HSPA6) and heat shock 60 kDa protein 1 (chaperonin) (HSPD1), but not DNAJB4, HSPA1A, HSPA5 and MOB family member 4, phocein (HSPE1), were significantly upregulated in frontal cortex area 8 in DLB when compared with MA (Table 4) . No modification in the expression of these genes was found in iLBD, but DNAJA1, HSPA4 and HSPA5 mRNA expression was significantly increased in PD (Tables 3 and 4) .
Finally, neurotransmission-related components gammaaminobutyric acid B receptor, 2 (GABBR2), gamma-aminobutyric acid A receptor, alpha 1 (GABRA1), glutamate decarboxylase 1 (brain, 67 kDa) (GAD1) and synaptic proteins neuropilin and tolloid-like 1 (NETO1), as well as synaptophysin (SYP) mRNAs, were found to be significantly downregulated in DLB when compared with MA. The expression of glutamate receptor, ionotropicmethyl D-aspartate 2A (GRIN2A) and glutamate receptor, ionotropic-methyl D-aspartate 2B (GRIN2B), and synaptic proteins member RAS oncogene family (RAB3A), Rabphilin 3A homolog (mouse) (RPH3A), synaptosomal-associated protein, 25 kDa (SNAP25), syntaxin binding protein 1 (STXBP1), synaptotagmin I (SYT1), synaptotagmin XIII (SYT13) and Synaptotagmin XVI (SYT16), was not altered in DLB (Table 4) .
DISCUSSION
This study presents the first transcriptome analysis of the frontal cortex integrating the whole spectrum of LBDs. In addition to performing a traditional gene-based differential expression analysis we considered a system biology approach based on coexpression networks. In particular, we applied WGNCA which allows the identification of modules of genes that are coexpressed across samples. These modules have to be interpreted with the understanding that such coexpression reflects a common biological function (e.g., from biochemical pathways to cell type defining signatures). We have identified some modules that correlate with LBDs. A proportion of genes included in those modules are also differentially expressed in a traditional gene-based comparative approach using the same microarray data and using independent case series for RTqPCR quantification and validation. The present study has also identified several hubs and PPI which raise the alert about putative biomarkers and targets for therapeutic intervention.
Lack of comorbidities in the present series implies the selection of a limited number of cases which minimizes the risk of bias. PD and DLB cases have concomitant AD-related pathology which was variable from one case to another. Thal phases were used to evaluate b-amyloid plaques; however, no distinction was made between diffuse and neuritic plaques.
Discussion is centred on selected genes, among those identified by differential expression analysis and weighted correlation networks, whose mRNA expression was assessed with RTqPCR. The transcriptome is relatively conserved in iLBD and PD as no genes surpass the threshold of significance when P-values are adjusted for multiple testing. This is in contrast with DLB where hundreds of genes show multiple testingcorrected significant expression differences when compared with MA individuals.
Dyneins are one deregulated cluster in LBDs. Five of seven assessed members are upregulated in iLBD and PD, and three of seven in DLB. Because of their ATP hydrolysis-mediated involvement in cytoplasmic transport (82) , early alteration of the cargo transport along neurites may be suggested in the frontal cortex within the LBD spectrum.
Expression of taste and olfactory receptors and down-stream obliged functional signaling pathways in the CNS and their deregulation in neurodegenerative diseases is intriguing. It is possible that these receptors in brain are not involved in the perception of odors and taste but rather correspond to new central chemoreceptors looking for putative ligands or interacting complementary receptors (30) . TASRs are significantly upregulated in frontal cortex in PD and DLB (33, 38) , and our findings further indicate that deregulation of TASRs in frontal cortex occurs in iLBD as well. Previous studies have shown altered protein synthesis machinery in the frontal cortex in PD and DLB from the nucleolus to the ribosome (36, 38). Nuclear alterations include increased nucleolar stress and altered synthesis of ribosomal RNAs, in addition to altered production of mRNAs. Our findings show altered mRNA expression of different molecules involved in RNA and DNA metabolism such as KAT2A which is upregulated in PD, and PNPT1, PAPOLA, RELA and DOT1Ls which are upregulated in DLB. PNPT1 and RELA are also upregulated in iLBD. Therefore, genes which encode proteins involved in the acetylation and methylation of histones, RNA processing and the modulation of NF-jB-mediated gene transcription are abnormally regulated in DLB and, to a lesser degree, in other disorders within the LBD spectrum. A primary effect of a-synuclein can be postulated, as a-synuclein is abnormally localized in the nucleus in neurons, and probably also in glial cells, in the frontal cortex in PD (36) .
Another deregulated cluster in LBD is related to innate inflammatory responses. This has been the subject of two detailed studies in PD and DLB (34, 38 ). An interesting aspect was the downregulation of cytokines and several mediators of the inflammatory response in the substantia nigra at early stages of PD (34) and the relatively low inflammatory response in the frontal cortex in DLB (38) , which is in line with previous observations pointing out the relatively low inflammatory response and enhanced dystrophic microglia in DLB (2, 88, 90) . This is further supported in the present study by downregulation of AIF1, which encodes the microglial marker IBA-1 in the frontal cortex in iLBD, thus suggesting early microglial alteration in LBDs.
Another DLB-associated module is related to heat-shock/chaperone proteins and is globally upregulated in DLB. Three out of ten assessed genes are upregulated in the frontal cortex in PD and six out of ten in DLB. These include DNAJA1, DNAJ4 and DNAJB1, the products of which act as heat shock protein 70 cochaperones, and chaperones HSPA4, HSPA6 and HSPD1.
Moreover, STIP1, a copartner in the HSP70/HSP90 activity in protein folding, is the top hub gene in this module and PPI together with HSPA1A and HSPA5. DNAJA1 and DNAJB1 are also among the top hub genes in this module. Importantly, the expression of this gene is increased in PD and DLB but significantly upregulated only in PD. Refolding and clearance of a-synuclein aggregates requires chaperones and the proteasome system (55). Our findings are consistent with the presence of abnormally aggregated a-synuclein in the cortex in DLB and also with previous observations of increased folding proteins and unfolded protein response in DLB (3, 16) .
We found a large gene coexpression module downregulated in DLB that is enriched in neuronal markers and in genes mainly involved in synaptic transmission. Synapses are altered in the cortex in PD and DLB (19, 20, 74, 85, 86) . a-synuclein is abundant in the pre-synaptic terminals, where it plays a role in synaptic function. Abnormal folding and oligomerization and formation of certain types of aggregates may directly produce synaptic damage, and may do so indirectly by exerting toxicity on mitochondria, lysosomes and cytoskeleton (56, 74, 85) . Notably, a top degree gene of the PPI subnetwork from this module is a-synuclein. In spite of being a PPI hub, SNCA is not a DEG between DLB and CTL as assessed by Limma, which highlights the importance of the present higher-complexity level study in revealing genes otherwise veiled in conventional differential expression methods.
Gene downregulation related to neurotransmission in the frontal cortex in DLB particularly involves GAD1, the product of which Table 3 . Quantification of the expression of selected genes corresponding to axonema and taste receptors clusters in MA, iLBD, PD and DLB. P-values have been adjusted using the BH method in each contrast and are indicated next to nominal P-values. P-values have been adjusted using the BH method in each contrast and are indicated next to nominal P-values.
catalyzes the synthesis of g-aminobutyric acid from L-glutamic acid, and GABA receptors GABBR2 and GABRA1, showing that the GABAergic system in frontal cortex is vulnerable to DLB. Other downregulated genes are NETO1, which encodes a protein involved in synaptic N-methyl-D-aspartic acid receptor complexes, and SYP, which encodes SYP, a major synaptic protein. In line with the present findings, loss of post-synaptic GABAreceptor markers has been reported in the occipital cortex in DLB (52) . SYP expression was previously reported as decreased in the occipital cortex in DLB as well (67) . The identification of deregulated M5 top hub gene, ATP6V1A, the product of which mediates the acidification of several intracellular organelles including synaptic vesicles, thereby facilitating synaptic transmission (12) , further points to altered synaptic function.
Other altered pathways identified in the M5-brown module, namely energy metabolism and mitochondrial function, and purine metabolism, have been the subject of previous analysis. Mitochondria and energy metabolism is altered in the frontal cortex in PD and DLB (37-39, 51, 68, 69, 76, 92) . Moreover, decreased enzymatic activity of complexes I-IV has been demonstrated in a subset of PD cases with dementia (38, 69) and in cases with DLB (37, 68) . Abnormal a-synuclein is localized in mitochondria in the frontal cortex in PD (38) and in the nucleus (36); thus, a possible link between altered nuclear and mitochondrial DNA/RNA processing and aberrant a-synuclein may be considered. The present study also shows two additional PPIs in module 5. Cytochrome c, somatic (CYCS) encodes a small heme protein localized in the inner membrane of the mitochondria which transports electrons from cytochrome b to the cytochrome oxidase complex (21) . Second, TPI1 encodes a protein which participates in glycolysis and glucogenesis (93) .
Regarding purine metabolism, our previous RT-qPCR studies revealed abnormal expression of several enzymes involved in purine metabolism in PD and DLB (35, 38) . No attempt was made to validate other important altered pathways such as those inked to the ubiquitin proteasome system (UPS) in LBDs revealed by microarrays, and interpretation of significantly altered regulation of certain top hub genes in M5 such as GSK3B and YWHAB, and M6 as LAPTM5 remains speculative.
CONCLUDING COMMENTS
The study of human cases is irreplaceable in the effort to gain understanding of the neurodegenerative diseases that are exclusive to human beings. It can be criticized the limited number of available cases suitable for molecular studies in the present series. This limitation may account for certain discrepancies between the observations obtained with arrays and the subsequent validations with RT-qPCR, and also by the observation of isolated deregulated genes which are apparently disconnected from highly represented deregulated clusters. In spite of these constraints, the present study, using selected samples with no comorbidity and adequate RNA preservation, has documented an extraordinary amount of information. Validation of the present findings should be expected in other independent series.
We used a "network medicine" approach to the study of LBDs aiming at unveiling changes in the transcriptome in frontal cortex area 8 which may affect particular metabolic pathways and biological functions. This approach is being increasingly used to discover relevant pathogenic effectors in neurodegenerative diseases (83) . Here, we show early alteration in the regulation of the axonema and particularly of dyneins, and of taste receptors in iLBD, maintained and augmented along with the progression of the LBD spectrum. Interestingly, innate inflammation is downregulated in iLBD as manifested by decreased AIF1 expression. It is worth mentioning that the expression of several cytokines and mediators of the inflammatory response is also reduced in iLBD (unpublished observations); the small number of cases assessed in this series precludes further evaluations, but our findings provide insights that will allow deepening to into the study of reduced innate inflammatory regulation at early stages of LBDs. We have also identified and validated deregulation of several pathways in the frontal cortex in DLB; this includes upregulation of RNA/DNA processing and chaperones, and downregulation of neurotransmission thereby revealing the vulnerability of the GABAergic system. Altered mitochondria and energy metabolism, protein synthesis, and altered purine metabolism regulation were the subject of previous studies. Our approach has also identified robust deregulated modules represented by several genes, hub genes and PPI subnetworks within these modules. These observations reveal potential candidates for further analysis as they may involve key pathogenic molecular events taking place in the frontal cortex in LBDs.
